Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Carcinoma

Adenocarcinoma

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy (VIP) techniques

Multi-port transperitoneal RARP with bilateral intrafascial nerve-sparing techniques

Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.

Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques

Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.

Multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques

Shancheng Ren, MD/PhD

Yi fan Chang

Shancheng Ren, PhD

This study is a two-arm, multicenter, randomized controlled clinical trial on whether single-port extraperitoneal VIP RARP is non-inferior to multi-port transperitoneal RARP in terms of functional recovery rate and other key metrics.

Multicenter enrollment of 480 patients with localized prostate cancer meeting enrollment criteria are randomized to undergo either single-port robotic extraperitoneal VIP radical prostatectomy or multi-port robotic transperitoneal bilateral intrafascial radical prostatectomy for perioperative data recording, treatment, and monitoring with 1 year follow up.

Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)

Potency recovery rate 3 months postoperatively, based on the patient's description of whether the erection is firm enough for sexual activity or intercourse.

The rate of recovery of continence postoperatively, measured in the number of pads used per day.

PSA status postoperatively，measured in ng/mL

Potency recovery rate will be assessed by patient's self-reported erectile firmness for sexual activity or intercourse, International Index of Erectile Dysfunction(IIEF-5) score（from 0-25 score, a higher score means a worse outcome）, and phosphodiesterase5 (PDE-5）inhibitor intake frequency according to patients' despciption (a higher intake means a worse outcome）.

Clavien-Dindo complication score measured in the following grades（a higher grade means a worse outcome） ： First grade：complications that do not require medication, surgery or endoscopic treatment.

Second grade： complications require to be treated with drugs, including blood transfusion and parenteral nutrition.

Third grade： complications that require surgery, endoscopy, or radiation therapy.

Fourth grade: the emergence of life-threatening complications, including cerebral hemorrhage, etc., which is also divided into 4a and 4b, 4a is single-organ dysfunction, 4b is mainly multi-organ dysfunction and injury.

Fifth grade: death.

Time elapsed from skin incision to placement of the final skin suture, measured in minutes

Estimated blood loss, measured in volume (mL)

Number of additional ports needed in surgery

Hospital stay, counted in days from the first day of hospitalization to discharge

Hospital stay, counted in days from the time of transfer to the post anesthesia care unit (PACU) to discharge

Shanghai Zhongshan Hospital

ShuGuang Hospital

The Third Affiliated Hospital of Naval Medical University

The First Affiliated Hospital of Guangzhou Medical University

Sir Run Run Shaw Hospital

Sichuan Provincial People's Hospital

Shanghai Changzheng Hospital

Professor，Chief of Urology

Symptoms and General Pathology

Hypothermia

Body Temperature Changes

Use of Hypothermia Cooling device only in the operating room. Intervention is Hypothermia Cooling Device.

Use of hypothermia cooling device in the operating room and up to five hours after surgery is intervention.

UroCool

Thomas Ahlering, MD

Robotic assisted laparoscopic radical prostatectomy (RLP) has gained widespread acceptance as a standard treatment for clinically localized prostate cancer. Despite the enhanced visualization and precise dissection afforded by the robotic platform, two major comorbidities affect a significant number of men: incontinence and erectile function.

Urinary continence and erectile function

It is commonly believed that the most important factor affecting continence is preservation of the external urinary sphincter complex which lies just below the prostate. Trauma to the urethral tissue itself after it is transected from the prostate and damage to the autonomic nerves that control this sphincter may lead to sphincteric dysfunction. In addition, dissection of the bladder may lead to bladder irritability which also plays a role in incontinence. Surgical removal of the prostate also causes significant inflammatory damage to the pelvic floor which likely delays recovery of urinary continence. The same trauma issues apply to sexual function.

One possible method to protect the nerves and other tissues from operative trauma may be the use of local hypothermia (cold-ischemia) to the pelvis. Local tissue hypothermia using ice, ice slush, or cold irrigation has been safely and routinely used for decades in humans during brain, heart, and kidney surgery to minimize organ damage. Yet, this technique has never been applied to prostate surgery. We will accomplish local cooling of the pelvis using a cooling balloon inserted into the rectum. The cooling balloon is powered by an FDA approved cooling system developed by Innercool therapies. Temperatures of 57-86 degrees F (22+/-8 degrees C).

2. 1. Selection of the Patients From June 2002 to August 2015, a total of 1,503 patients underwent RARP. During this period, perioperative data, including postoperative functional outcomes, were prospectively collected using a customized database; our ethics committee approved the data collection. Erectile function was assessed using the sexual health profile for men (SHIM) score at 3, 9, 15, and 24 months and then annually after surgery, and the duration of pad-free continence recovery was asked by a non-physician third party. In our institution, RH was applied during RARP for all patients from February 2008 to March 2015 (consecutively between the 671st and 1459th cases). Among the recruited patients, 789 men (52.6%) underwent HP, leaving the other 711 (47.4%) as controls.

The inclusion criteria for this study were as follows: (1) bilateral nerve-sparing RARP (over 70%) and (2) a minimum follow-up of 15 months. The exclusion criteria were as follows: (1) men with a history of salvage radiation therapy, chemotherapy, or hormone therapy after RARP (n=98) and (2) the presence of a high-risk disease with an initial prostate-specific antigen (PSA) level over 20 ng/ml or biopsy Gleason score over 8, which may influence the refining surgical plane around the neurovascular bundle (NVB), thereby affecting the degrees of nerve-sparing strategy at the time of surgery (n=275). Further, (3) the initial 100 cases were excluded to avoid potential bias from the learning period. From a cohort of 1,503 patients, 59 (3.92%) men whose potency outcome within 15 months was not assessed were also excluded from the study. Finally, 930 patients were selected for the analysis; half of the procedures (n=466, 50.1%) were performed under RH and the remaining other half (n=464, 49.9%) as normothermal controls.

2. 2. Endpoints of the Study The primary endpoints of this study were the SHIM score and the rate of potency regain, which was defined as a SHIM score \>17 in the RH and control groups 15 months after surgery. Considering the proven impacts of age and preoperative SHIM scores on the recovery of potency, the groups were further divided into the young and potent (YP: age \<65 years and SHIM score ≥22, n=409, 43.9%) subgroup and susceptible for impotency (SI: age ≥65 years or SHIM score \<22, n=512, 55.1%) counterpart and investigated the sexual function of the YP subgroup. The secondary endpoints were the duration of pad-free continence regain and the rate of continence recovery within 3 months after surgery, especially in the YP subgroup.

2.3. Surgical Protocol for RH All procedures were performed by a single surgeon. RH was achieved by devising an endorectal cooling balloon system (ECB) as previously reported \[2, 4, 5\]. In brief, a 40-cm, 24-F, 3-way latex urethral catheter was placed inside a 5 × 2.5-inch elliptic latex balloon that distended at a low pressure and conformed to the rectal wall without excessive deformations. The lubricated ECB was inserted just inside the anus and anchored by inflating the catheter balloon to 20 ml. The ECB was then distended and cycled continuously with cold saline (4°C) by gravity 40 cm above the patient. The ECB volume was \~200 ml. A 9-F esophageal probe (Smiths Medical ASD, Rockland, MA) was used to obtain the intracorporeal temperature readings directly along the anterior surface of the rectum/NVB.

Use of Hypothermia During Robotic Prostatectomy

Hypothermic Nerve Sparing Radical Prostatectomy

The primary aim is confirmation of the feasibility and safety using an improved, more efficient and less labor intensive cooling balloon in patients undergoing hypothermic nerve-sparing RLP. Continence is defined as no protective urinary pad use as reported by the patient in response to the very first question on page 1 of the sample questionnaire.

University of California, Irvine

Adverse events were not broken by arm as both groups used the same device and underwent the same procedure leading to a large cohort of patients who underwent cooling. Adverse event reporting was irrespective of arm and cannot be separated. Adverse events were also assessed irrespective of terms.

Both arms:

An adverse event (AE) is any undesirable experience (sign, symptom, significant laboratory abnormality, illness, or other medical event) occurring to a patient that appears or worsens during a clinical study, regardless of etiology.

* Mild - Awareness of signs or symptoms that are easily tolerated. Signs and symptoms are transient and only of minor irritant type and cause no loss of time from normal activities; symptoms do not require medication or a medical evaluation.
* Moderate - Discomfort severe enough to cause interference with usual activities. Symptoms may require treatment but not extended hospitalization or intensive care for the patient.
* Severe - Incapacitating with inability to do work or usual activities. Signs and symptoms may be of systemic nature or require medical evaluation and/or treatment that requires prolonged hospital stay

General Adverse Events

Use of Hypothermia Cooling device only in the operating room

UroCool: Hypothermia Endorectal Device

Hypothermia Only OR

Use of hypothermia cooling device in the operating room and up to five hours after surgery.

UroCool: Hypothermia Endorectal Device

Hypothermia in OR + Recovery

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

United States

Region of Enrollment

Linda Huynh

Feasibility and Safety Using an Improved, More Efficient and Less Labor Intensive Cooling Balloon in Patients Undergoing Hypothermic Nerve-sparing RLP in Participants Determined by Return to Continence

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)	NCT06238713	Prostate Adenoc... Localized Prost...	Single-port ext... Multi-port tran...	18 Years - 75 Years	Shanghai Changzheng Hospital
Use of Hypothermia During Robotic Prostatectomy	NCT00915031	Prostate Cancer	UroCool	18 Years -	University of California, Irvine
Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)	NCT06238713	Prostate Adenoc... Localized Prost...	Single-port ext... Multi-port tran...	18 Years - 75 Years	Shanghai Changzheng Hospital

Spots Global Cancer Trial Database for potency

Every month we try and update this database with for potency cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for potency

Every month we try and update this database with for potency cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for potency cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.